No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Antonin Holy?

Dr. Antonin Holy

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Senior Research Scientist

Institute of Organic Chemistry and Biochemistry

Position, Development of New Treatments

Institute of Organic Chemistry and Biochemistry

Institute for Organic Chemistry and Biochemistry



Web References (28 Total References)

Designer Drugs For HIV (October 2006) [cached]

Dr. Antonin Holy of the Institute of Organic Chemistry and Biochemistry in Prague, Czech Republic, writing in the journal Antiviral Research, reviews the work of his group and others on the modification of NRTI-like drugs, opening their closed ring structures, adding on chemical groups to alter their electric charge and increase their ability to enter cells, and so on.

Today's News [cached]

One international grantee, Dr. Antonin Holy, Senior Research Scientist at the Institute of Organic Chemistry and Biochemistry in Prague, will modify two compounds he discovered, both FDA-approved therapies, to create new formulations that fight resistant virus."Dr.Holy's research may extend the treatment options of patients who have become resistant to current anti-HIV therapies," Dr. Laurence said.

Czech Republic: Europe's New Biotech Corridor at BIO 2005 | Today's Stem Cell Research [cached]

Dr. Antonin Holy, whose work in the development of new treatments for the suppression of AIDS (HIV) and hepatitis at the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic resulted in 2001 and 2002 U.S. Food and Drug Administration approval of Viread, a treatment for AIDS, and Hepsera, a B-hepatitis drug.Both were produced by Gilead Sciences and based on a compound discovered in Dr. Holy's Prague laboratory. - New Jersey Business online media newspaper news ebusiness research journal NJBiz [cached]

research effort between Dr. Antonin Holy, Institute for Organic Chemistryand Biochemistry, Academy of Sciences of the Czech Republic (IOCB) in

Gilead Sciences And The Institute Of Organic Chemistry And [cached]

Donation by Gilead Honors Leadership of Dr. Antonin Holy in Antiviral Drug Discovery and Development

Foster City, CA & Prague, Czech Republic - Gilead Sciences, Inc. announced a donation to The Institute of Organic Chemistry and Biochemistry at the Academy of Sciences of the Czech Republic (IOCB) for the establishment of a Gilead Sciences Research Centre.Gilead will provide a $1.1 million annual donation to IOCB for an initial five-year term to fund the Centre's operations and ongoing research activities.
IOCB will use the donations to establish and support the Gilead Sciences Research Centre, which will consist of selected research groups led by the scientists at IOCB.In addition, Gilead and IOCB will establish the Gilead Distinguished Chair in Medicinal Chemistry.Dr. Antonin Holy, IOCB, will be the first to hold the position of Distinguished Chair and will continue to lead research efforts in nucleoside and nucleotide drug discovery.The operation of the Research Centre will be governed by a Steering Committee and monitored by an Advisory Board.
In 1991 and 1992, Gilead entered into license agreements with IOCB and the Rega Institute for Medical Research, Katholic University in Leuven, Belgium that cover a large number of nucleotide analogue compounds and structures.Several of these nucleotide compounds (specifically HPMPC, PMPA and PMEA) discovered through a collaborative research effort between Dr. Antonin Holy and Dr. Erik DeClercq, Rega Institute, were developed by Gilead, resulting in Vistide(R) (cidofovir injection) for the treatment of CMV retinitis in AIDS patients, Viread(R) (tenofovir disoproxil fumarate) for the treatment of HIV infection and Hepsera(R) (adefovir dipivoxil) for the treatment of chronic hepatitis B.
"We are pleased to be able to honor the contribution of Dr. Holy and the productive collaboration between Gilead and IOCB over the years through this donation, which will fuel IOCB's leading role in scientific research and drug discovery."
"The scientific pursuit of new targets, new compounds and novel mechanisms for identifying or treating diseases is our most important priority," said Dr. Antonin Holy.

Similar Profiles

Other People with this Name

Other people with the name Holy

Alexandra Holy
Capital Impact Partners

Richard Holy
DB Schenker Limited

Maja Holy
Stanford University

Jeff Holy
Washington Real Estate Commission

Nicholas Holy
Weisbrod Matteis & Copley PLLC

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory